Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

3.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission.

The Lancet. Haematology·2026
Same author

Evaluation of Red Blood Cell Biomechanics in the Setting of Cancer-Associated Anemia and Chemotherapy.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

DIC in pregnancy: lessons from an international registry of the International Society for Thrombosis and Hemostasis: Communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same author

Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics.

Nucleic acid therapeutics·2026
Same author

Megakaryocytes Internalize and Are Activated by Immune Complexes.

Circulation research·2026

Related Experiment Video

Updated: Jan 18, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K

Developing an artificial intelligence-generated peptide targeting platelet-type von Willebrand disease.

Thomas David Daniel Kazmirchuk1,2,3, Jiashu Wang1,2,3, Loredana Bury4

  • 1Department of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Blood Advances
|September 12, 2025
PubMed
Summary

A new peptide inhibitor, G14, selectively targets the abnormal platelet glycoprotein Ibα interaction in platelet-type von Willebrand disease (PT-VWD). This discovery offers potential for targeted therapy and diagnostics for this rare bleeding disorder.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.0K

Related Experiment Videos

Last Updated: Jan 18, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.0K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Platelet-type von Willebrand disease (PT-VWD) is a rare bleeding disorder caused by gain-of-function mutations in platelet glycoprotein Ibα (GPIbα).
  • These mutations result in hyperactive protein-protein interactions (PPIs) between GPIbα and von Willebrand factor (VWF), leading to pathological platelet aggregation.
  • Currently, no targeted therapies exist for PT-VWD, despite its well-defined genetic basis.

Purpose of the Study:

  • To develop a peptide inhibitor that selectively targets the aberrant GPIbα-VWF interaction in PT-VWD.
  • To validate the efficacy and specificity of designed peptide inhibitors using in vitro and ex vivo assays.
  • To explore the potential of identified inhibitors as diagnostic tools for PT-VWD.

Main Methods:

  • Utilized the In Silico Protein Synthesizer to design and screen 10,000 peptides for affinity and specificity against mutated GPIbα (GPIbαMet239Val).
  • Conducted functional validation using in vitro assays with GPIbαGly233Val and Met239Val variants, alongside ex vivo platelet assays from PT-VWD patients.
  • Employed structural modeling to predict the binding site and mechanism of action of the lead peptide inhibitor.

Main Results:

  • Identified a peptide inhibitor, G14, demonstrating potent and selective inhibition of the GPIbαGly233Val, Met239Val-VWF PPI.
  • G14 exhibited picomolar affinity (6.6 pM) for the mutated GPIbα and selectively disrupted the VWF interaction without affecting wild-type GPIbα or VWF alone.
  • Ex vivo assays showed G14 inhibited VWF binding and ristocetin-induced platelet agglutination in PT-VWD patient samples, with no effect on healthy controls.

Conclusions:

  • The G14 peptide represents a highly specific inhibitor of the disease-associated GPIbα-VWF interaction, providing proof-of-concept for targeted PT-VWD therapeutics.
  • The specificity of G14 suggests its potential utility as a diagnostic tool for identifying PT-VWD.
  • The study highlights the effectiveness of artificial intelligence in designing precision therapeutics for disease-specific PPIs.